Bayesian Capital Management’s Ingevity NGVT Stock Holding History

Bayesian Capital Management’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,746	Closed	-$607K	–	632
2019 Q1	$607K	Buy	+5,746	New	+$577K	0.12%	246
2016 Q4	–	Sell	-8,400	Closed	-$387K	–	664
2016 Q3	$387K	Buy	+8,400	New	+$355K	0.25%	143

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's NGVT Position: Q2 2019 in Review

Bayesian Capital Management sold out of Ingevity (NGVT) in Q2 2019, closing a stake of 5,746 shares — an estimated $607K sold.

Bayesian Capital Management first reported a position in NGVT in Q3 2016 and held it in 2 quarters. The position peaked at $607K in Q1 2019. 334 funds tracked by Wall St. Rank hold NGVT as of Q2 2019.

Bayesian Capital Management reported no remaining Ingevity position as of Q2 2019 after selling out during the quarter.
Bayesian Capital Management sold 5,746 Ingevity shares in Q2 2019, an estimated $607K.
Bayesian Capital Management first reported a position in Ingevity in Q3 2016 and held it in 2 quarters.
Bayesian Capital Management's Ingevity position peaked at $607K in Q1 2019.
334 funds tracked by Wall St. Rank held Ingevity as of Q2 2019.

Based on Bayesian Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.